Galera Therapeutics Inc

OTC:GRTX

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Malvern, Pennsylvania and currently employs 30 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The firm's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). The company is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). The company is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The firm is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.